In a report issued on October 11, Jonathan Chang from Leerink Partners maintained a Hold rating on Athenex (ATNX – Research Report), with a price target of $2.00. The company’s shares closed last Wednesday at $2.71, close to its 52-week low of $2.50.
According to TipRanks.com, Chang is a 3-star analyst with an average return of 3.4% and a 29.7% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Harpoon Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Athenex with a $3.50 average price target.
The company has a one-year high of $15.00 and a one-year low of $2.50. Currently, Athenex has an average volume of 1.24M.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATNX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment involves in discovery and development of cancer supportive therapies. The Global Supply Chain Platform segment consists of manufacturing and marketing of API, medical devices, and clinical products. The Commercial Platform segment engages in manufacturing and selling of commercial pharmaceutical products. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.